HCA Healthcare, Inc. (HCA)
| Previous close | 310.31 |
| Open | 312.35 |
| Bid | 317.39 x 900 |
| Ask | 317.80 x 1000 |
| Day's range | 312.81 - 318.30 |
| 52-week range | 215.96 - 335.83 |
| Volume | |
| Avg. volume | 1,092,951 |
| Market cap | 83.986B |
| Beta (5Y monthly) | 1.67 |
| PE ratio (TTM) | 16.75 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.64 (0.85%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Business Wire
Clinical Trial by Harvard Pilgrim Health Care Institute, HCA Healthcare, UCI Health and CDC Identifies Strategy to Rapidly Detect and Respond to Hospital Outbreaks Using Algorithm-Driven Technology
BOSTON & NASHVILLE, Tenn. & ORANGE, Calif. & ATLANTA, April 23, 2024--An automated tool that improves outbreak detection for hundreds of pathogens successfully served as an early warning system to find and respond to potential hospital outbreaks, as reported today in NEJM Evidence.
- Business Wire
Fortune Names HCA Healthcare One of the World’s Most Admired Companies
NASHVILLE, Tenn., April 22, 2024--HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced it has been named on Fortune’s 2024 World’s Most Admired Companies list. This year, HCA Healthcare is ranked first overall in its industry.
- Business Wire
Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection
NASHVILLE, Tenn. & ORANGE, Calif. & ATLANTA & BOSTON, April 19, 2024--Two large multi-state studies uncovered a highly effective way to improve antibiotic selection for patients hospitalized with pneumonia or urinary tract infections (UTI), enabling better antibiotic stewardship in hospitals, according to research studies published today in the Journal of the American Medical Association (JAMA).
